92 related articles for article (PubMed ID: 18997214)
1. The appropriate role of cost-effectiveness in determining device coverage: a case study of drug-eluting stents.
Firth BG; Cooper LM; Fearn S
Health Aff (Millwood); 2008; 27(6):1577-86. PubMed ID: 18997214
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of drug-eluting stents in a US Medicare setting:a cost-utility analysis with 3-year clinical follow-up data.
Bischof M; Briel M; Bucher HC; Nordmann A
Value Health; 2009; 12(5):649-56. PubMed ID: 19490551
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of everolimus- versus paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization (from the SPIRIT-IV Trial).
Amin AP; Reynolds MR; Lei Y; Magnuson EA; Vilain K; Durtschi AJ; Simonton CA; Stone GW; Cohen DJ
Am J Cardiol; 2012 Sep; 110(6):765-70. PubMed ID: 22651880
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of percutaneous coronary intervention with drug-eluting stents versus bypass surgery for patients with 3-vessel or left main coronary artery disease: final results from the Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) trial.
Cohen DJ; Osnabrugge RL; Magnuson EA; Wang K; Li H; Chinnakondepalli K; Pinto D; Abdallah MS; Vilain KA; Morice MC; Dawkins KD; Kappetein AP; Mohr FW; Serruys PW;
Circulation; 2014 Sep; 130(14):1146-57. PubMed ID: 25085960
[TBL] [Abstract][Full Text] [Related]
5. Comparative effectiveness review within the U.K.'s National Institute for Health and Clinical Excellence.
Chalkidou K
Issue Brief (Commonw Fund); 2009 Jul; 59():1-12. PubMed ID: 19639713
[TBL] [Abstract][Full Text] [Related]
6. Long-term clinical and economic analysis of the Endeavor zotarolimus-eluting stent versus the cypher sirolimus-eluting stent: 3-year results from the ENDEAVOR III trial (Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
Eisenstein EL; Leon MB; Kandzari DE; Mauri L; Edwards R; Kong DF; Cowper PA; Anstrom KJ;
JACC Cardiovasc Interv; 2009 Dec; 2(12):1199-207. PubMed ID: 20129546
[TBL] [Abstract][Full Text] [Related]
7. Clinical and economic outcomes of liberal versus selective drug-eluting stent use: insights from temporal analysis of the multicenter Evaluation of Drug Eluting Stents and Ischemic Events (EVENT) registry.
Venkitachalam L; Lei Y; Stolker JM; Mahoney EM; Amin AP; Lindsey JB; Kennedy KF; Pencina MJ; Lopez JJ; Kleiman NS; Cohen DJ;
Circulation; 2011 Aug; 124(9):1028-37. PubMed ID: 21844081
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of drug-eluting stents including the economic impact of late stent thrombosis.
Filion KB; Roy AM; Baboushkin T; Rinfret S; Eisenberg MJ
Am J Cardiol; 2009 Feb; 103(3):338-44. PubMed ID: 19166686
[TBL] [Abstract][Full Text] [Related]
9. Saying no isn't NICE - the travails of Britain's National Institute for Health and Clinical Excellence.
Steinbrook R
N Engl J Med; 2008 Nov; 359(19):1977-81. PubMed ID: 18987366
[No Abstract] [Full Text] [Related]
10. Economic evaluation of drug-eluting stents compared to bare metal stents using a large prospective study in Ontario.
Goeree R; Bowen JM; Blackhouse G; Lazzam C; Cohen E; Chiu M; Hopkins R; Tarride JE; Tu JV
Int J Technol Assess Health Care; 2009 Apr; 25(2):196-207. PubMed ID: 19331710
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of percutaneous coronary intervention versus bypass surgery from a Dutch perspective.
Osnabrugge RL; Magnuson EA; Serruys PW; Campos CM; Wang K; van Klaveren D; Farooq V; Abdallah MS; Li H; Vilain KA; Steyerberg EW; Morice MC; Dawkins KD; Mohr FW; Kappetein AP; Cohen DJ;
Heart; 2015 Dec; 101(24):1980-8. PubMed ID: 26552756
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of drug-eluting stents in patients at high or low risk of major cardiac events in the Basel Stent KostenEffektivitäts Trial (BASKET): an 18-month analysis.
Brunner-La Rocca HP; Kaiser C; Bernheim A; Zellweger MJ; Jeger R; Buser PT; Osswald S; Pfisterer M;
Lancet; 2007 Nov; 370(9598):1552-9. PubMed ID: 17980734
[TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of drug-eluting stents as compared with bare metal stents in patients with coronary artery disease.
Wisløff T; Atar D; Sønbø Kristiansen I
Am J Ther; 2013; 20(6):596-601. PubMed ID: 21822114
[TBL] [Abstract][Full Text] [Related]
14. Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV Trial.
Bakhai A; Stone GW; Mahoney E; Lavelle TA; Shi C; Berezin RH; Lahue BJ; Clark MA; Lacey MJ; Russell ME; Ellis SG; Hermiller JB; Cox DA; Cohen DJ;
J Am Coll Cardiol; 2006 Jul; 48(2):253-61. PubMed ID: 16843171
[TBL] [Abstract][Full Text] [Related]
15. Seeing the NICE side of cost-effectiveness analysis: a qualitative investigation of the use of CEA in NICE technology appraisals.
Bryan S; Williams I; McIver S
Health Econ; 2007 Feb; 16(2):179-93. PubMed ID: 16960851
[TBL] [Abstract][Full Text] [Related]
16. Is there an alternative to quality-adjusted life years for supporting healthcare decision making?
Beresniak A; Dupont D
Expert Rev Pharmacoecon Outcomes Res; 2016 Jun; 16(3):351-7. PubMed ID: 27139424
[TBL] [Abstract][Full Text] [Related]
17. How should cost-effectiveness analysis be used in health technology coverage decisions? Evidence from the National Institute for Health and Clinical Excellence approach.
Williams I; Bryan S; McIver S
J Health Serv Res Policy; 2007 Apr; 12(2):73-9. PubMed ID: 17407655
[TBL] [Abstract][Full Text] [Related]
18. NICE, drug-eluting stents and the limits of trial data.
Mohindra R
Heart; 2009 Mar; 95(6):505-6; author reply 506. PubMed ID: 19252009
[No Abstract] [Full Text] [Related]
19. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
Griebsch I; Coast J; Brown J
Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
[TBL] [Abstract][Full Text] [Related]
20. Drug reimbursement recommendations by the National Institute for Health and Clinical Excellence: have they impacted the National Health Service budget?
Mauskopf J; Chirila C; Birt J; Boye KS; Bowman L
Health Policy; 2013 Apr; 110(1):49-59. PubMed ID: 23434292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
